2026 Competition Pharma 
MedCity News
AUGUST 15, 2024
The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come.
Pharmaceutical Technology
MAY 11, 2023
The global pharma industry experienced a 9% drop in social media posts on internet of things in Q1 2023 compared with the previous quarter, with the highest share accounted for U.S. Of the 50 leading companies in the pharma industry, U.S. Buy the report here.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 10, 2023
Its ability to accelerate R&D programmes, energise real-time clinical decision making and sharpen connections between pharma organisations and clients is clear and they can combine to positively impact patient outcomes. Pharma is a highly regulated industry and that is often why it is slow to adopt new technologies,” says Kazuki.
European Pharmaceutical Review
MARCH 13, 2023
“Not only does the location has offer competitive costs [but it has] proximity to our existing European-based production and commercial operations.” Full operations is provisionally planned for late 2026. The new plant will support the growing biosimilars sector. Work on the biologics plant in Slovenia is set to begin this year.
pharmaphorum
SEPTEMBER 30, 2022
Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No.
European Pharmaceutical Review
SEPTEMBER 14, 2023
Ultimately, this puts European businesses at a competitive disadvantage compared to other companies worldwide. Once adopted by the Council, the regulatory proposals are planned to come into force on 1 July 2028 (for BEFIT) and on 1 January 2026 (for the transfer pricing proposal).
PM360
SEPTEMBER 21, 2023
Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.
Expert insights. Personalized for you.
122 
Let's personalize your content